Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $22 from $16 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
- Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
- Immunovant price target lowered to $41 from $44 at Guggenheim
- Immunovant Raises $550 Million Through Stock Offering
- Immunovant’s Strategic Advancements and Promising Pipeline Drive Buy Rating